Creating new CRISPR tools for gene editing therapy
Official title: Developing novel Type 1 CRISPR tools for gene editing therapy
Funded at Genetobe INC. · NIH-10821108 · Data updated 2026-11-12
This study is working on new CRISPR tools to make gene editing safer and more precise for people with sickle cell disease, aiming to create better treatments with fewer risks.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Genetobe INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | February 15, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $293,319 |
| NIH project number | 1R41GM153041-01 |
| Project ID | NIH-10821108 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with genetic disorders, particularly those affected by sickle cell disease.
✕Less likely to help
Patients with conditions not related to genetic disorders or those who do not have access to gene editing therapies may not benefit from this research.
What this research studies
This research focuses on developing innovative CRISPR tools to enhance gene editing therapies, particularly for conditions like sickle cell disease. By exploring Type I CRISPR systems, the project aims to improve the precision and safety of gene editing, addressing limitations of current methods that rely on Cas9. The approach involves using non-double-strand break techniques to minimize potential damage to DNA, which could lead to safer treatments for patients. If successful, these advancements could pave the way for more effective therapies for genetic disorders.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene editing therapies for patients with genetic disorders like sickle cell disease.
How similar studies have gone: Previous research has shown promise in using CRISPR technology for gene editing, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Genetobe INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Hou, Zhonggang — Genetobe INC.
- Study coordinator: Hou, Zhonggang
Related research
Other NIH-funded projects on the same topics.
-
New treatments for metabolic diseases in cystic fibrosis patients
This study is looking at new medications that could help people with cystic fibrosis manage diabetes and liver issues by targeting specific glucose transporters, especially for those who have had worsening health after starting a treatment called Trikafta.
-
Developing a targeted treatment for alcohol-related liver disease
This study is looking at how to use a new treatment method to help people with alcohol-related liver disease by focusing on a specific gene that affects liver damage, with the goal of finding better ways to prevent or treat this serious condition.
-
Gene editing therapy for a genetic disorder causing hearing and vision loss
This study is testing a new gene editing treatment for people with Usher syndrome type 3A, which causes hearing and vision loss, to see if it can safely fix the faulty gene and help improve their hearing and vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.